Physician profile

Stephen D Cederbaum

Clinical Genetics (M.D.) · Los Angeles, CA

NPI 1932121217

$27,661.25

in general payments reported to CMS, 2019-2025

6 companies · $818 in 2025

The $818 reported for 2025 was more than what a typical Clinical Genetics (M.D.) provider received nationally (typical 2025 total: $255).

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Consulting Fee$7,200.00
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program$1,500.00
Food and Beverage$288.04

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Ptc Therapeutics, INC. $12,004.41 2021-2025
Horizon Therapeutics Plc $7,881.27 2022
Modernatx, INC. $3,132.00 2023
Eton Pharmaceuticals, INC. $1,750.00 2022
Immedica Pharma US, INC. $1,500.00 2024
Biomarin Pharmaceutical INC. $1,393.57 2019-2025

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Stephen D Cederbaum

$27,661.25

in general payments reported 2019-2025

Years
2019-2025
Top company
Ptc Therapeutics, INC.
Context
The $818 reported for 2025 was more than what a typical Clinical Genetics (M.D.) provider received nationally (typical 2025 total: $255).

https://glasscript.com/doctor/446887/stephen-d-cederbaum

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.